Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1B4CQ)

• Drug Name: RTL-1000 Drug Info
• Synonyms: VG-1000; VGI-303; Recombinant t-cell ligand (multiple sclerosis), Artielle

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM1B4CQ

Molecule-Related Drug Atlas

Drug(s) Targeting T-cells (T-cells)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATG-Fresenius S	DM4VJ5Q	Transplant rejection	NE84	Phase 3	[3]
DiabeCell	DMK6FYR	Insulin-dependent diabetes	5A10	Phase 2	[4]
TVI-Kidney-1	DMGYSZ0	Renal cell carcinoma	2C90	Phase 2	[5]
Baltaleucel-T	DM3WCL4	Diffuse large B-cell lymphoma	2A81	Phase 2	[6]
T2c-001	DM06GDC	Congestive heart failure	BD10	Phase 2	[4]
BPX-501	DMIMA4V	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[6]
AX-024	DMRQ32K	Multiple sclerosis	8A40	Phase 1	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cells (T-cells)	TTXQYT6	NOUNIPROTAC	Binder	[2]

References

• [1] ClinicalTrials.gov (NCT00411723) Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis. U.S. National Institutes of Health.
• [2] RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14.
• [3] Clinical pipeline report, company report or official report of Neovii Biotech.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Clinical pipeline report, company report or official report of TVAX Biomedical.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)